Atlas Venture is a Cambridge, Massachusetts based early-stage, biotech-focused venture firm. Atlas seeks to invest in the technology and life sciences sectors with a focus on personalized medicine, medical technologies, therapeutics, biotechnology, biology, drug discovery technologies, therapeutic platforms, novel biopharmaceutical products, novel therapeutics, novel drug discovery platforms, therapeutic products, innovative biomedical technologies, diagnostics, and medical devices.
Atlas Venture is an early-stage venture capital firm that invests in life sciences startup companies in the U.S. Atlas is headquartered in Cambridge, Massachusetts where the majority of its investments are located. Atlas rolled out its eleventh biotech fund totaling $350 million in June 2017, after closing its tenth fund in April 2015 with $280 million in commitments. The team is led by five investment partners: Kevin Bitterman, Bruce Booth, Jean-Francois Formela, David Grayzel, and Jason Rhodes.
Atlas has been investing in biotech since 1993, but the firm invested in both life sciences and IT until 2014, when it separated those businesses, with the Atlas Venture brand remaining associated with its biotech bets. The IT side became the seed-stage firm Accomplice.
Originally formed in 1980, Atlas historically invested in both life sciences and information technology startup companies. In October 2014, Atlas announced its shift to a biotech-only venture capital firm, with the technology-focused investment team forming a new firm, Accomplice, to continue investing in information technology startups.
Previously as a diversified firm, Atlas had raised over $3.0 billion of investor commitments across nine venture capital funds. The firm raised $705 million for its 2000-vintage fifth fund, $600 million for its 2001-vintage sixth fund, $385 million for its 2006-vintage seventh fund, $283 million for its 2009-vintage eighth fund, and $265 million for its 2013-vintage ninth fund.
At its largest, the firm held European offices in London, Paris, and Munich, and a West Coast office based in Seattle, Washington, in addition to the Boston-area headquarters. Today, the firm operates from a single office in Cambridge, Massachusetts.
Atlas Venture has made 492 investments. The firm has had 127 exits, including PillPack, Integral Ad Science, and Carbon Black. Atlas Venture has raised a total of $2.4B across 7 funds, one of them being Atlas Venture Opportunity Fund I. This fund was announced on Jan 2, 2019, and raised a total of $250M.
Atlas has invested in over 150 life sciences startups since it began investing in the sector in 1990. Atlas invests in a range of therapeutic areas, including immuno-oncology, autoimmunity/inflammation, neuroscience, gene/cell therapy and editing, and anti-infectives. The current portfolio includes gene/cell editing/therapy companies AVROBIO, Generation Bio, Intellia Therapeutics, Obsidian Therapeutics, and Unum Therapeutics; oncology companies Bicycle Therapeutics, Kyn Therapeutics, Replimune, Surface Oncology, and Unum Therapeutics; autoimmunity companies Nimbus Therapeutics and Padlock Therapeutics; anti-infectives company Spero Therapeutics; synthetic biology company Synlogic; RNA companies miRagen Therapeutics and Translate Bio; and CNS companies Cadent Therapeutics, Disarm Therapeutics, Navitor, and Rodin Therapeutics; and novel platform companies Accent Therapeutics, Kymera Therapeutics, Gemini Therapeutics, HotSpot Therapeutics, and Akero. Notable prior exits from Atlas’ life sciences portfolio include Actelion, Adnexus Therapeutics, Alnylam Pharmaceuticals, Annovation Biopharma, Annovation Biopharma, ArQule, Arrow Therapeutics, Arteaus Therapeutics, Avila Therapeutics, CoStim Pharmaceuticals, Crucell, deCODE genetics, Delinia, Exelixis, IFM Therapeutics Inc., Micromet, Momenta Pharmaceuticals, MorphoSys, Nimbus Apollo, Novexel, Padlock Therapeutics, Stromedix, and U3 Pharma.
- Within technology, the firm focuses on payments, SMB, consumer-facing innovation, advances in biology, next-generation infrastructure, security, consumer services, small business infrastructure, fintech, emerging web service companies, next-generation media, gaming, and social technologies, enterprise and internet infrastructure, big data and mobile infrastructure, internet-related businesses and communications.
- Within life sciences, it focuses on biopharmaceuticals.
- It also invests in silicones, consumer discretionary, and internet and direct marketing retail, internet software and services, IT services, security software, memory chips, and broadband telecommunication services.
The firm prefers to invest in companies based in the Europe and United States with a focus on New England, Boston, Maine, Connecticut, New Hampshire, Rhode Island, Vermont, California, and San Francisco Bay Area. Its initial investment ranges from $0.25 million to $15 million per transaction. The firm prefers to be a lead investor and seeks board representation in its portfolio companies. Massachusetts.
Atlas announce closing of $250m fund
Atlas Venture raised a $250m to support early stage biotech companies.
Atlas Venture Opportunity Fund I
Atlas Venture Fund XI, L.P.
Atlas rolled out its eleventh biotech fund totaling $350 million in June 2017, after closing its tenth fund in April 2015 with $280 million in commitments.
Atlas Venture Fund X, L.P.
Atlas Venture Fund IX, L.P.
Atlas Venture Fund VIII, L.P.
Atlas Venture Fund VII
Atlas Venture Fund VI, L.P.
GARY D. GLICK
GERRALDINE (GERRY) HARRIMAN
HOWARD L. KAUFMAN
5AM raises nearly $500M in two new biotech venture funds
As market shifts, Atlas Venture closes a $250 million fund to support its breakaway biotech bets
Atlas Venture - Visnick & Caulfield
Atlas Venture Announces $250 Million Opportunity Fund
Atlas Venture bags $250 million for its first opportunity fund - Healthcare Opportunity
Atlas Venture Closes First Opportunity Fund, at $250M | FinSMEs
Atlas Venture investor portfolio, rounds & team
Atlas Venture Jobs, Employment | Indeed.com
Atlas Venture Launches Generation Bio - EEI-BIOTECHFINANCES
Atlas Venture raises $250m | Private Equity International
Atlas Venture raises $250M for later-stage investments | FierceBiotech
Atlas Venture raises $250M for Opportunity Fund
Atlas Venture Rounds Up $250 Million for Later-Stage Biotech Fund
Biogen Idec, Atlas Venture Pump $17M into Ataxion
Exclusive: Atlas Venture is splitting up
Is JPM Week worth it from a press perspective?
Kevin Bitterman, Partner, Atlas Venture - Akero Therapeutics
LifeSciVC | Bruce Booth, partner at Atlas Venture, blogs on all facets of early stage biotech.
Moving HQ to Boston, AtScale CEO Chris Lynch Talks VCs, Tech Scene
Our Year In Review: Annual Talk On Macro, Biotech, and Atlas | LifeSciVC
Plunkett's Investment & Securities Industry Almanac 2008
Predicting The Next Dominoes to Fall in 2019 | LifeSciVC
See Ya Later, Techies: Atlas Venture Goes It Alone, Scoops Up $280M For Biotech
Startups Weekly: VCs celebrate the new year the only way they know how
Venture Capital and New Technology Based Firms
Documentaries, videos and podcasts
Atlas Venture 2018 Year in Review B. Booth
Feb 11, 2019
Chris Lynch, Atlas Venture // Data Driven #28 // June 2014 (Hosted by FirstMark Capital)
Jun 26, 2014
Kinvey & Atlas Venture
Aug 28, 2012
Our Year In Review: Annual Talk On Macro, Biotech, and Atlas | LifeSciVC
February 12, 2019
F-Star Alpha Limited